LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | A443654 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 525 | 4513 | 0.1164 | -0.2168 |
MDA-MB-231 | OSI-027 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3459 | 4513 | 0.7665 | 0.6784 |
MDA-MB-231 | XMD11-85h | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3800 | 4513 | 0.8419 | 0.7823 |
MDA-MB-231 | HG-6-64-01 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 1410 | 4513 | 0.3125 | 0.0532 |
MDA-MB-231 | WH-4-025 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 861 | 4513 | 0.1908 | -0.1144 |
MDA-MB-231 | WZ-4-145 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 2984 | 4513 | 0.6612 | 0.5334 |
MDA-MB-231 | XMD16-144 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 1315 | 4513 | 0.2915 | 0.0243 |
MDA-MB-231 | Brivanib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4270 | 4513 | 0.9461 | 0.9258 |
MDA-MB-231 | Buparlisib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2909 | 4513 | 0.6446 | 0.5106 |
MDA-MB-231 | BX-912 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 1614 | 4513 | 0.3576 | 0.1153 |
MDA-MB-231 | Canertinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3446 | 4513 | 0.7636 | 0.6745 |
MDA-MB-231 | Celastrol | 1.11 | uM | LJP6 | 72 | hr | 1235 | 852 | 4513 | 0.1888 | -0.1170 |
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 407 | 4513 | 0.0902 | -0.2528 |
MDA-MB-231 | CGP60474 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 344 | 4513 | 0.0762 | -0.2721 |
MDA-MB-231 | CHIR-99021 | 1.11 | uM | LJP6 | 72 | hr | 1235 | 3544 | 4513 | 0.7853 | 0.7043 |
MDA-MB-231 | CP724714 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4619 | 4513 | 1.0234 | 1.0322 |
MDA-MB-231 | CP466722 | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4178 | 4513 | 0.9256 | 0.8976 |
MDA-MB-231 | Crizotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2201 | 4513 | 0.4876 | 0.2944 |
MDA-MB-231 | Momelotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2108 | 4513 | 0.4672 | 0.2663 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 653 | 4513 | 0.1447 | -0.1779 |
MDA-MB-231 | Dasatinib | 1.11 | uM | LJP6 | 72 | hr | 1235 | 661 | 4513 | 0.1466 | -0.1752 |
MDA-MB-231 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 2184 | 4513 | 0.4840 | 0.2895 |
MDA-MB-231 | Enzastaurin | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4883 | 4513 | 1.0820 | 1.1129 |
MDA-MB-231 | Erlotinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 4322 | 4513 | 0.9576 | 0.9416 |
MDA-MB-231 | Foretinib | 1.11 | uM | LJP5 | 72 | hr | 1235 | 1371 | 4513 | 0.3038 | 0.0413 |